Scintigraphic Monitoring of Catheter-Port Systems in Type I Diabetics with Continuous Insulin Therapy

Place and duration of study: The study was conducted at diabetic clinic B.V. Hospital/Q.A.M.C Bahawalpur from December 1st, 2004 to March 15th, 2005. Background: Diabetes mellitus and hepatitis C infections are common and emerging problems of the society. Either diabetes mellitus is common in chronic hepatitis C patients as reported initially by Ellison and co-workers or hepatitis C infection is more frequent in diabetes mellitus. We want to study the frequency of hepatitis c infection in diabetes mellitus. Objectives: To study the frequency of hepatitis C infection in diabetic patients and to note any risk factors of diabetic patients predisposing to hepatitis C infection. Designs: A cross-sectionalObservational-descriptive analytic study. Subjects and Methods: A total of 250 consecutive diabetic patients of either sex were compared with 6574 blood donors for hepatitis c infection .They were evaluated for hepatitis C infection by using Enzyme Linked Immunosorbant Assay (ELISA-3) which is an anti-HCV anti body test. On basis of this test, the patients were divided into two groups, anti-HCV +ve and anti-HCV -ye. Different variables of these patients were studied and compared in these two groups Variables studied were as follows:- Age, Sex, BMI, Mode of therapy area of their residence(rural or urban) Duration of diabetes mellitus, Blood pressure, Nephropathy and Control of diabetes mellitus. Results: Among a total of 250 patients, 120 (48%) were male and 130 (52%) were female. Two hundred and forty-four (97.6%) patients were of type-II DM and 06 (2.4%) patients were of type-I DM. 22 (8.8%) patients were on insulin therapy while 228 (91.2%) were on oral hypoglycemic agents. Anti-HCV test was positive in 69 (27.6%) diabetic patients as compared to blood donors 41 (0.62%). In anti-HCV positive group, longer duration of diabetic mellitus (15yrs 15.94%), poor control of diabetic mellitus(87%), insulin therapy(17.39%) hypertension(91.3%) and nephropathy(94.2%) were the significant vari ables while BMI, age, sex and whether they were belonging to either rural or urban area were not significant in both the groups. Conclusion: Hepatitis C infection is common in diabetic patients as compared to control group (27.6% vs 0.62%). Out of diabetic patients HCV infection is more common with longer duration of diabetic mellitus, poor control of diabetic mellitus, hypertension, nephropathy and insulin therapy.

Download Full-text

Use of the pen delivery system for intensive insulin therapy in college-age students with type I diabetes

Journal of Adolescent Health ◽

10.1016/0197-0070(91)90050-v ◽

1991 ◽

Vol 12 (5) ◽

pp. 373-376 ◽

Cited By ~ 5

Author(s):

H. Peter Chase ◽

Satish K. Garg ◽

Sandy L Hoops ◽

Sherrie Harris ◽

William Wilcox

Keyword(s):

Insulin Therapy ◽

Delivery System ◽

Intensive Insulin Therapy ◽

Type I Diabetes ◽

Type I ◽

College Age

Download Full-text

Intraperitoneal Insulin Reduces Plasma Leptin Concentration in Diabetic Patients on CAPD

Peritoneal Dialysis International ◽

10.1177/089686080002000106 ◽

2000 ◽

Vol 20 (1) ◽

pp. 27-32 ◽

Cited By ~ 4

Author(s):

Pasi I. Nevalainen ◽

Jorma T. Lahtela ◽

Jukka Mustonen ◽

Amos Pasternack

Keyword(s):

Insulin Therapy ◽

Tertiary Care ◽

University Hospital ◽

Glucose Disposal ◽

Diabetic Patients ◽

Type I ◽

Intraperitoneal Insulin ◽

End Stage ◽

Plasma Leptin ◽

Glucose Disposal Rate

Objective To determine the effects of subcutaneous (SC) and intraperitoneal (IP) insulin on serum leptin concentration in type I diabetic patients with end-stage renal failure treated with continuous ambulatory peritoneal dialysis (CAPD). Design Prospective, open, before–after study. Setting Tertiary-care university hospital. Participants Twelve type I diabetic patients with stabilized CAPD, age 43.9 ± 2.8 years, and duration of diabetes 30.4 ± 3.5 years. Intervention After stabilized CAPD therapy, all patients were treated first with SC insulin for a median of 3 months, and thereafter with IP insulin for another 3 months. Main Outcome Measures Plasma leptin, insulin sensitivity with euglycemic clamp, and glycemic and uremic status after both treatment periods. Results During SC insulin therapy, plasma leptin concentration was significantly higher than during IP insulin (19.8 ± 5.9 ng/mL and 12.8 ± 6.2 ng/mL, respectively; p < 0.001). Leptin concentration was higher in CAPD patients and was related to body mass index in both genders. No correlation was detected between plasma leptin and fasting insulin, glycemic control, glucose disposal rate, or serum lipids. Conclusion Plasma leptin concentration is lower during IP insulin therapy compared to SC insulin. Insulin has probably a direct effect on both peritoneal leptin clearance and adipose tissue leptin production. The significance of leptin in regulating appetite and anorexia in uremia remains unclear.

Download Full-text

Lipoprotein composition in the insulin-deficient non-acidotic phase of type I diabetic patients and early evolution after the start of insulin therapy

Clinica Chimica Acta ◽

10.1016/0009-8981(93)90067-e ◽

1993 ◽

Vol 223 (1-2) ◽

pp. 113-120 ◽

Cited By ~ 7

Author(s):

Jordi L. Reverter ◽

Mariano Senti ◽

Juan Rubiés-Prat ◽

Anna Lucas ◽

Isabel Salinas ◽

...

Keyword(s):

Insulin Therapy ◽

Early Evolution ◽

Diabetic Patients ◽

Type I ◽

Lipoprotein Composition

Download Full-text

Insulin therapy corrects NK cells abnormality in type I diabetes mellitus patients

Biomedicine & Pharmacotherapy ◽

10.1016/0753-3322(96)85098-0 ◽

1996 ◽

Vol 50 (1) ◽

pp. 38-39 ◽

Cited By ~ 2

Author(s):

S Guastafierro ◽

F Sessa ◽

T Cerciello ◽

C Cuomo ◽

G Giannetti

Keyword(s):

Diabetes Mellitus ◽

Insulin Therapy ◽

Nk Cells ◽

Type I Diabetes ◽

Type I Diabetes Mellitus ◽

Type I

Download Full-text

Intensive Insulin Therapy for Treatment of Type I Diabetes

Diabetes Care ◽

10.2337/diacare.13.12.1265 ◽

1990 ◽

Vol 13 (12) ◽

pp. 1265-1283 ◽

Cited By ~ 62

Author(s):

I. B. Hirsch ◽

R. Farkas-Hirsch ◽

J. S. Skyler

Keyword(s):

Insulin Therapy ◽

Intensive Insulin Therapy ◽

Type I Diabetes ◽

Type I

Download Full-text

An overview of insulin therapy in pharmacotherapy of diabetes mellitus type I

International Journal of Community Medicine and Public Health ◽

10.18203/2394-6040.ijcmph20180418 ◽

2018 ◽

Vol 5 (3) ◽

pp. 834

Author(s):

Abdulkareem Alotaibi ◽

Bashayer Al Sultan ◽

Reem Buzeid ◽

Mohammad Almutairi ◽

Eman Alghamdi ◽

...

Keyword(s):

Diabetes Mellitus ◽

Insulin Therapy ◽

Health Management ◽

Glucose Monitoring ◽

Insulin Injection ◽

Haemoglobin A1c ◽

Type I ◽

Meal Planning ◽

Type 1 Dm

Type 1 diabetes mellitus is a chronic disease, which characterizes itself with body’s inability to produce insulin from pancreas. This condition can happen from different autoimmune processes, which subsequently leads into destruction of beta cells in pancreas, the cells responsible for production of insulin. This condition account for about 5-10% of all different forms of diabetes, which should be taken very seriously since its incidence seems to be increasing worldwide and it can result in different devastating short and long-term complications. Management and approaches in patients with type 1 DM is of major concern worldwide since in the lack of proper management these patients cannot survive. Therefore, it is very important to have a multidisciplinary health management team that can have full focus on every aspect of this condition from continuous glucose monitoring, meal planning, screening for different complications to insulin therapy, which is the mainstay in treatment of patients in this group. American Diabetes Association (ADA) suggests using patient’s age in establishment of glycaemic goals, with targets for pre-prandial, bedtime and haemoglobin A1c levels. It is very important to educate patients on how to adjust the level of their insulin injection according to the amount of carbohydrate intake, premeal blood glucose, and anticipated activity. Insulin is and will remain the most important treatment approach in patients suffering from type 1 DM. According to recommendations of ADA, it is best when patients with type 1 DM are treated with multiple daily doses of insulin injections, such as three to four daily basal and prandial injections, or continuous subcutaneous insulin infusion devices should be used.

Download Full-text